The Belgian-French bank has closed the sale of FSA, its troubled US monoline insurer, for $817m. Dexia is keeping FSA’s $17bn portfolio of toxic assets. But after losing E3.2bn last year, the bank is making money in the first half. Cautious confidence in its future is justified.